In 2012, the hepatitis C universe changed forever when Gilead's Sovaldi was approved. Finally, there was an excellent drug that could eliminate the infection almost all the time. But some strains of HCV are tougher than others to treat. But now, Gilead strikes again.
With the issue of drug pricing currently in the news, The New York Times ran an editorial decrying prices that are "too high," while failing to truly address the real issues. Instead, the paper took the easy way out by linking Turing's price gouging to pricing methods of established pharmaceutical makers.
Catch the latest news on concerns regarding Gilead's $84,000 hepatitis C treatment drug Sovaldi, the declining sales of traditional cigarettes, and why prior authorization could be hurting the health care system
If there is a better example of the law of unintended consequences we have never seen it. The incredibly successful battle against HIV/AIDS has saved many lives, and will no doubt continue to save many more. Once HAART (highly active antiretroviral therapy) drugs, aka cocktails, became available in 1995, there was a steep drop in the number of AIDS deaths in the US.